Literature DB >> 23702124

Anticoagulation in management of antiphospholipid antibody syndrome in pregnancy.

Michael D Lockshin1.   

Abstract

Knowledge of antiphospholipid antibodies and their impact on pregnancy continues to evolve. A variety of antiphospholipid antibodies have been identified, but not all of them seem to be pathologic for pregnancy outcome. Understanding of which patients are at high risk for adverse pregnancy outcome and the most effective treatment will require clinical trials based on risk stratification and long-term follow-up of infants.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702124      PMCID: PMC3664954          DOI: 10.1016/j.cll.2013.01.001

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  53 in total

1.  Non-criteria manifestations of antiphospholipid syndrome.

Authors:  D Erkan; M D Lockshin
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

2.  Autoimmunity: effectiveness of treatments for pregnant women with APS.

Authors:  Shari E Gelber; Jane E Salmon
Journal:  Nat Rev Rheumatol       Date:  2010-04       Impact factor: 20.543

Review 3.  Domain I of beta2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome.

Authors:  Y Ioannou; A Rahman
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

Review 4.  Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?

Authors:  S S Pierangeli; D Erkan
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

5.  Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for factor V Leiden.

Authors:  Tracy Manuck; D Ware Branch; Yinglei Lai; Baha Sibai; Catherine Y Spong; George Wendel; Katharine Wenstrom; Philip Samuels; Steve N Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner
Journal:  J Reprod Immunol       Date:  2010-05-02       Impact factor: 4.054

6.  Anti-β2-glycoprotein I antibodies are highly prevalent in a large number of Brazilian leprosy patients.

Authors:  S L Ribeiro; H L Pereira; N P Silva; A W Souza; E I Sato
Journal:  Acta Reumatol Port       Date:  2011 Jan-Mar       Impact factor: 1.290

7.  Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy.

Authors:  D M Cohn; M Goddijn; S Middeldorp; J C Korevaar; F Dawood; R G Farquharson
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

8.  Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.

Authors:  Melissa J Mulla; Jan J Brosens; Larry W Chamley; Ian Giles; Charis Pericleous; Anisur Rahman; Shawna K Joyce; Britta Panda; Michael J Paidas; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2009-08       Impact factor: 3.886

9.  Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.

Authors:  Carl A Laskin; Karen A Spitzer; Christine A Clark; Mark R Crowther; Jeff S Ginsberg; Gillian A Hawker; John C Kingdom; Jon Barrett; Michael Gent
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

Review 10.  Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation.

Authors:  Jane E Salmon; Guillermina Girardi
Journal:  J Reprod Immunol       Date:  2007-04-05       Impact factor: 4.054

View more
  2 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

2.  Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.

Authors:  Louise C Kenny; Douglas B Kell
Journal:  Front Med (Lausanne)       Date:  2018-01-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.